EARSS Annual Report 2002 - European Centre for Disease ...


EARSS Annual Report 2002 - European Centre for Disease ...

6 Summary


The European Antimicrobial Resistance Surveillance System (EARSS) is an international network

funded by the Director General for Health and Consumer Protection (DG SANCO) of the European

Commission and the Dutch Ministry of Health, Welfare and Sports. It maintains a comprehensive

surveillance and information system that links national networks by providing comparable and

validated data on the prevalence and spread of major invasive bacteria with clinically and

epidemiologically relevant antimicrobial resistance in Europe.

EARSS collects routinely generated antimicrobial susceptibility testing (AST) data, provides spatial

trend analyses and makes up-to-date feedback available via an interactive Website at

http://www.earss.rivm.nl. Over 700 laboratories serving 1100 hospitals in 28 European countries

regularly submit routine data for major indicator pathogens (Streptococcus pneumoniae,

Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Escherichia coli). On the

basis of the 2002 laboratory/hospital questionnaire, the overall hospital catchment population of the

EARSS network is estimated at more than 100 million inhabitants in the European region, with

national coverage rates that range between 20% and 100% for individual countries. In 2002, 93% of

the eligible laboratories also participated in the annual external quality assurance (EQA) exercise,

which is jointly organised by EARSS, the United Kingdom External Quality Assurance Scheme (UK-

NEQAS) and the Centre Réfèrence des Antibiotiques (CRAB). Despite the different guidelines used

in various countries, the overall concordance of susceptibility results was of sufficient quality, which

shows that pooling and analysis of EARSS surveillance data render valid results for most pathogenspecific

susceptibility data.

For the last 4 years, the resistance showed a clear north–south gradient for penicillin non-susceptible

S. pneumoniae (PNSP), with high levels of macrolide co-resistance in several of the southern and

the northern countries. The dynamics of the global epidemic of methicillin-restistant S. aureus

(MRSA) has slowed down in the United Kingdom and Ireland, but it showed the fastest increasing

proportions in Germany and Austria between 1999 and 2002. Scandinavian countries have been

spared from this trend, but the Netherlands saw the beginning of a trend towards higher MRSA rates

in 2002. Vancomycin-resistant enterococci (VRE), with proportions less than 10% in most countries,

have been reported. The six countries that reported higher rates of VRE also had large MRSA

proportions, which suggests an epidemiological association. E. coli resistance to the

aminopenicillins is common in the European region; only Finland and Sweden report proportions of

less than 30%. Resistance of E. coli to third-generation cephalosporins remained less than 6% in

most countries. Greater proportions were noted for some eastern European countries that appeared

to have problems with extended spectrum beta-lactamase (ESBL)-producing strains. However, there

was a consistent and marked rise in fluoroquinolone-resistant E. coli in most European countries,

eight of which witnessed an 1.5-fold increase or more in only 2 years (2001 – 2002). This trend may

to be related to the widespread acceptance and use of newer fluoroquinolones with enhanced activity

against gram-positive pathogens. We predict that both hospital and community-acquired E. coli

infection may become a new challenge as a pathogen that will be difficult to treat in the European

region in the years to come.

EARSS has become an internationally accepted surveillance initiative, which provides meaningful

information about the status and trends of antimicrobial resistance in the European region. The

possible relationship between antimicrobial resistance and consumption will be explored in close

More magazines by this user
Similar magazines